Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

Share this content:

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

Sponsors and Collaborators

GlaxoSmithKline 

Contact

US GSK Clinical Trials Call Center 

877-379-3718

GSKClinicalSupportHD@gsk.com 

Investigators
GSK Clinical Trials
GlaxoSmithKline
  
ClinicalTrials.gov Identifier

NCT00424255

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs